ARS Pharmaceuticals
SPRY
115 hedge funds and large institutions have $533M invested in ARS Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 46 increasing their positions, 24 reducing their positions, and 21 closing their positions.
2,238% more call options, than puts
Call options by funds: $19.2M | Put options by funds: $821K
92% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 24
14% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 21
2.53% more ownership
Funds ownership: 62.06% → 64.59% (+2.5%)
2% more funds holding
Funds holding: 113 → 115 (+2)
13% less capital invested
Capital invested by funds: $612M → $533M (-$79M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$12.7M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.23M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.83M |
| 4 |
State Street
Boston,
Massachusetts
|
+$2.23M |
| 5 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
+$2.15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sio Capital Management
New York
|
-$2.82M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$1.07M |
| 3 |
AIC
AWM Investment Company
New York
|
-$1.02M |
| 4 |
Capstone Investment Advisors
New York
|
-$739K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$735K |
SPRY Hedge Fund Activity: Q2 2024 in Review
115 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in ARS Pharmaceuticals (SPRY) for Q2 2024, worth a combined $533M — down 13% from $612M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new SPRY positions and 21 closed out — a net gain of 3 holders — while 46 added to existing stakes and 24 trimmed.
The largest buyer was BlackRock, adding an estimated $12.7M. The largest seller was Sio Capital Management, cutting an estimated $2.82M.
- 115 institutional investors held ARS Pharmaceuticals (SPRY) as of Q2 2024, up from 113 in Q1 2024.
- Funds reported $533M of ARS Pharmaceuticals stock for Q2 2024, down 13% quarter-over-quarter.
- 24 funds opened new ARS Pharmaceuticals positions in Q2 2024 and 21 closed out, a net change of +3 holders.
- The largest ARS Pharmaceuticals buyer in Q2 2024 was BlackRock, an estimated $12.7M added.
- The largest ARS Pharmaceuticals seller in Q2 2024 was Sio Capital Management, an estimated $2.82M sold.
Based on aggregated 13F filings for Q2 2024.